BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), a
biotechnology company developing targeted, safe treatment options for cancer,
this morning announced the presentation of initial safety data from the
combination study of its lead candidate, Bria-IMT, with pembrolizumab
[KEYTRUDA®; manufactured by Merck & Co., Inc. (NYSE: MRK)] and confirmation
of positive proof of concept data on Bria-IMT for advanced breast cancer at the
2018 San Antonio Breast Cancer Symposium. “I am very excited about our data
continuing to show robust biological activity of Bria-IMT™ in advanced breast
cancer,” Dr. Bill Williams, president and CEO of BriaCell, stated in the news
release. “These findings also reinforce our product development strategy for
Bria-OTS™, BriaCell’s novel off-the-shelf personalized immunotherapy, by
showing predictability of the anti-tumor responses in patients using a
relatively simple and inexpensive HLA test.”
“Based on the data of three proof of concept studies
to-date, Bria-IMT™ has shown the ability to produce powerful immune responses
and elicit tumor regression even in heavily pre-treated patients with very
advanced disease,” Williams continued. “We are highly confident of our strategy
to use Bria-IMT™ in combination with KEYTRUDA®, an approved treatment for
multiple cancer indications, and expect synergistic activity of this
combination in patients with advanced breast cancer. We look forward to additional
clinical data and expect to share details at upcoming scientific meetings.”
To view the full press release, visit http://ibn.fm/NlEQR
About BriaCell
BriaCell is an immuno-oncology focused biotechnology company
developing targeted and safe approaches for the management of cancer. BriaCell
is currently conducting a Phase I/IIa clinical trial of Bria-IMT, its lead
candidate, in a combination study with pembrolizumab [Keytruda; manufactured by
Merck & Co., Inc.] or ipilimumab [Yervoy; manufactured by Bristol-Myers
Squibb Company]. The combination study is listed in ClinicalTrials.gov as
NCT03328026. BriaCell is developing Bria-OTS, an off-the-shelf personalized
immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments
are personalized to match the patient without the need for personalized
manufacturing. Bria-OTS, which is expected to cover over 90 percent of the
patient population, is designed to produce a potent and selective immune response
against the cancer of each patient while eliminating the time, expense, and
complex manufacturing logistics associated with other personalized
immunotherapies. For more information, visit the company’s website at www.BriaCell.com
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer
No comments:
Post a Comment